{
    "clinical_study": {
        "@rank": "139644", 
        "arm_group": {
            "arm_group_label": "Lyral\u00ae Sensitive Subjects", 
            "arm_group_type": "Experimental", 
            "description": "Subjects were patch tested with one experimental T.R.U.E. Test allergen panel containing 0.40 mg/cm^2, 0.20 mg/cm^2, and 0.10 mg/cm^2 of Lyral\u00ae and a negative control and a second panel containing the marketed reference allergen (20 mg of Lyral\u00ae 5%, in petrolatum). The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare ascending doses of investigational T.R.U.E. Test\n      allergens to the marketed petrolatum reference allergen."
        }, 
        "brief_title": "Clinical Evaluation of Lyral\u00ae Dose Response Study", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Contact Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Contact"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single-center, double-blind, randomized study to compare the diagnostic\n      performance (primary) and safety (secondary) of ascending doses of hydroxyisohexyl\n      3-cyclohexene carboxaldehyde (Lyral\u00ae) 0.40 - 0.20 - 0.10 mg/cm\u00b2and a control patch\n      (\u00df-cyclodextrin and Povidone (PVP)), in 20 adult subjects who have a clinical history of\n      contact dermatitis and have tested positive (current or previous patch test) to Lyral\u00ae or\n      Fragrance Mix 2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females 18 years of age and older.\n\n          2. Clinical history of contact dermatitis and positive patch test (current or previous)\n             to either Lyral\u00ae or Fragrance Mix 2; otherwise in good general health.\n\n          3. Unable to become pregnant or willing to use an acceptable method of contraception to\n             prevent pregnancy if female of childbearing potential; Inability to become pregnant\n             would include all male subjects and female subjects who are postmenopausal for at\n             least 1 year, or surgically sterile- have had a hysterectomy, bilateral ovariectomy,\n             uterine ablation or bilateral tubal ligation.\n\n             Acceptable methods of contraception include: 1) systemic birth control (the same type\n             of birth control for at least 3 months prior to entering the study and continuation\n             of this type of birth control throughout the study); 2) double barrier methods\n             (condom with spermicide or diaphragm with spermicide); 3) intra uterine device; 4)\n             vasectomized partner; or 5) abstinence from sexual intercourse.\n\n          4. Have read and signed the consent form and are able to fulfill the study requirements\n             and make all required visits.\n\n        Exclusion Criteria:\n\n          1. Lactation or pregnancy, determined by urine pregnancy test (UPT) for females of\n             childbearing potential.  UPT must be conducted prior to patch placement.\n\n          2. Treatment with topical corticosteroids on or near the test area during the previous 7\n             days.\n\n          3. Treatment with systemic corticosteroids or immunosuppressives during the previous 7\n             days. (Inhaled treatments are permitted.)\n\n          4. Treatment with ultraviolet (UV) light, including tanning, during the previous 3\n             weeks.\n\n          5. Acute dermatitis outbreak or dermatitis on or near the test area on the back.\n\n          6. Participation in another clinical study involving an investigational drug, treatment\n             or device currently or within the previous 3 weeks.\n\n          7. Unable to comply with activity restrictions (e.g., protecting test panels from excess\n             moisture due to showering or vigorous activity).\n\n          8. Unable or unwilling to comply with multiple return visits."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028182", 
            "org_study_id": "12 1PL 201"
        }, 
        "intervention": {
            "arm_group_label": "Lyral\u00ae Sensitive Subjects", 
            "description": "T.R.U.E. Test allergen panel (0.40 mg/cm^2, 0.20 mg/cm^2, 0.10 mg/cm^2 and negative control)", 
            "intervention_name": "Lyral\u00ae", 
            "intervention_type": "Biological", 
            "other_name": "T.R.U.E. Test Lyral Allergen Panel (experimental)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Patch Test", 
            "Allergy Testing", 
            "Contact dermatitis", 
            "Lyral allergen", 
            "Fragrance Mix allergen"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Odense", 
                    "country": "Denmark", 
                    "zip": "DK-5000"
                }, 
                "name": "University of Southern Denmark Institute of Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral\u00ae) Dose Response Study", 
        "overall_official": {
            "affiliation": "Department of Dermatology and Allergy Centre Odense University Hospital", 
            "last_name": "Evy Paulsen, Md, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Subjects were patch tested with one experimental T.R.U.E. Test allergen panel containing 0.40 mg/cm^2, 0.20 mg/cm^2, and 0.10 mg/cm^2 of Lyral\u00ae and a negative control and a second panel containing the marketed reference allergen (20 mg of Lyral\u00ae 5%, in petrolatum). The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application. A response is considered positive if it is graded 1+ (erythema, infiltration, discrete papules), 2+ (erythema, papules, infiltration, discrete vesicles) or 3+ (coalescing vesicles, bullous eruption) during at least one post removal visit.", 
                "measure": "Percentage of Participants who exhibit Positive Responses to each Allergen Concentration", 
                "safety_issue": "No", 
                "time_frame": "3-21 days following application"
            }, 
            {
                "description": "Subjects were patch tested with one experimental T.R.U.E. Test allergen panel containing 0.40 mg/cm^2, 0.20 mg/cm^2, and 0.10 mg/cm^2 of Lyral\u00ae and a negative control and a second panel containing the marketed reference allergen (20 mg of Lyral\u00ae 5%, in petrolatum). The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application. Negative responses are graded no response, doubtful responses include faint macular or homogenous erythema with no infiltration and irritant responses include discrete, patchy, follicular, or homogenous erythema with no infiltration.", 
                "measure": "Percentage of Participants who exhibit Negative, Doubtful or Irritant Responses at Day 3, Day 4 and Day 21", 
                "safety_issue": "No", 
                "time_frame": "3-21 days following application"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tape irritation is graded on a 4 point scale: None (no tape irritation), Weak (faint to definite pink), Moderate (moderate erythema, definite redness) and Strong (severe erythema, very intense redness). Percentage of response will include weak, moderate and strong reactions.\nItching and Burning are graded on a 4 point scale: None (no discomfort), Weak (minimal discomfort), Moderate (definite discomfort) and Strong (significantly bothersome, possible interference with sleep or daily activity). Percentage of response will include weak, moderate and strong responses.", 
                "measure": "Percentage of Participants who exhibit Irritation (tape reaction), Itching and/or Burning Resulting from Application of the Investigational and Reference Allergen Panels", 
                "safety_issue": "Yes", 
                "time_frame": "Day 2: 48 hours after application"
            }, 
            {
                "description": "Late reactions initially occur at 7-10 days after application of the panels Persistent reactions appear at Day 2-4 and persist through Day 7-21", 
                "measure": "Percentage of Subjects who exhibit Late or Persistent Reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Days 2-21"
            }
        ], 
        "source": "Allerderm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allerderm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}